Surgery Partners (SGRY) Q4 2024: 17.5% Revenue Growth Highlights Robust Organic and Acquisition-Driven Expansion
Surgery Partners demonstrated sustained momentum with strong organic growth and accretive acquisitions driving revenue and adjusted EBITDA expansion. Margin improvement initiatives and disciplined capital deployment underpin the company’s confident 2025 outlook. Regulatory headwinds remain minimal, positioning the company well for continued market share gains.
Summary
- Disciplined Growth Execution: Consistent organic and acquisition-driven expansion fuels reliable margin improvement.
- Operational Leverage in Early Stages: Revenue cycle and procurement initiatives remain nascent, offering ongoing margin enhancement potential.
- Regulatory Resilience: Minimal Medicaid exposure and favorable site neutrality positioning mitigate legislative risk.
Business Overview
Surgery Partners operates as a leading healthcare services company specializing in short-stay surgical facilities, including ambulatory surgery centers (ASCs), surgical hospitals, and ancillary services. The company generates revenue primarily through surgical cases across multiple specialties, with a focus on high-acuity procedures such as orthopedics. Its business model emphasizes partnerships with physicians to deliver cost-effective, high-quality surgical care in outpatient settings.
Performance Analysis
In the fourth quarter of 2024, Surgery Partners reported a 17.5% increase in revenue to $864.4 million, propelled by a 5.6% same-facility revenue growth and a 5.1% increase in surgical case volume. For the full year, revenue reached $3.1 billion, marking a 13.5% growth over 2023. Adjusted EBITDA expanded 15.1% in Q4 to $163.8 million with a margin of 18.9%, and grew 16% for the full year to $508.2 million, reflecting a 30 basis point margin expansion to 16.3%.
The growth was largely fueled by strong organic performance, notably an 11% increase in orthopedic cases driven by a 50% surge in total joint procedures, which accounted for a significant portion of the company’s surgical volume. The addition of 14 surgical robots in 2024 supported higher acuity procedures and physician recruitment efforts. Acquisitions totaling nearly $400 million and the opening of eight de novo facilities further augmented growth.
- Case Mix Shift: Higher acuity orthopedic procedures and total joint replacements drove volume and revenue growth.
- Capital Deployment Impact: Strategic acquisitions and facility expansions contributed meaningfully to revenue and margin expansion.
- Margin Expansion Drivers: Procurement efficiencies, revenue cycle improvements, and integration synergies supported margin gains.
Despite strong revenue growth, net loss attributable to Surgery Partners was $108.5 million in Q4, influenced by a non-cash valuation allowance on deferred tax assets related to technical accounting requirements. Operating cash flow improved to $111.4 million in Q4 and $300.1 million for the full year, supporting liquidity of over $770 million combining cash and revolver capacity.
Executive Commentary
"We are pleased to report another year of mid-teens growth, while continuing to expand margin. Our 2024 results are a continuation of the Company's consistent and predictable organic growth, with same-facility revenue growth of 8.0%. During 2024 we deployed nearly $400 million on accretive acquisitions and opened eight de novo facilities to further expand our portfolio of high quality, short-stay surgical facilities offering exceptional value to our patients, health plans, and the communities we serve."
Eric Evans, CEO
"We enter 2025 with a liquidity position of over $770 million, which enhances our confidence and ability to continue to fund accretive M&A without the need to access the capital markets. We expect margin expansion in 2025 and beyond driven by procurement and revenue cycle initiatives, as well as integration benefits from recent acquisitions and contributions from de novos."
Dave Doherty, CFO
Strategic Positioning
1. Robust Organic Growth through Specialty Focus and Physician Partnerships
Surgery Partners’ strategy centers on expanding high-acuity specialties, particularly orthopedics, evidenced by 11% growth in orthopedic cases and 50% growth in total joint procedures in 2024. The company’s physician partnership model facilitates targeted recruiting and service line expansion, with over 750 new physicians added in 2024, many aligned with orthopedic specialties. This organic growth engine is complemented by the deployment of advanced surgical robotics, enhancing procedural capabilities and competitive differentiation.
2. Accretive M&A and De Novo Facility Development
The company’s disciplined capital allocation includes nearly $400 million invested in acquisitions in 2024, focusing on specialty surgical facilities with higher acuity profiles. Surgery Partners opened eight de novo facilities in 2024 and plans to develop at least ten annually, often in partnership with experienced physicians. These investments yield both immediate EBITDA contributions and long-term organic growth, with de novos typically reaching break-even within the first year.
3. Margin Expansion via Operational Efficiency and Scale
Margin improvement efforts leverage procurement efficiencies, revenue cycle optimization, and integration synergies from acquisitions. The company reports early-stage but promising improvements in revenue cycle metrics, including a three-day reduction in days sales outstanding (DSO) quarter-over-quarter. Supply chain management has effectively mitigated tariff-related cost pressures, limiting exposure to approximately 1% of costs. These initiatives underpin the company’s expectation of continued margin expansion in 2025.
4. Regulatory Environment and Site Neutrality Positioning
Surgery Partners benefits from minimal exposure to Medicaid and state-based funding, constituting less than 5% of revenue, reducing vulnerability to policy changes. The company supports site neutrality legislation, which aims to shift procedures to lower-cost outpatient settings, positioning its short-stay surgical facilities as beneficiaries of potential case migration from traditional acute care hospitals. Worst-case revenue impact from site neutrality is estimated at approximately 1%, with likely upside from case inflows.
5. Strong Balance Sheet and Liquidity Support Growth Strategy
With $270 million in cash and $501.5 million in revolver capacity, Surgery Partners maintains over $770 million in liquidity. The company’s leverage ratio stands at 3.7 times net debt to EBITDA under its credit agreement, with a target to reduce leverage to mid-threes over the next five years. Fixed interest rates and interest rate caps mitigate refinancing risk, supporting sustained investment in growth initiatives without capital market dependence.
Key Considerations
Surgery Partners’ 2024 results reflect strategic execution across multiple fronts, balancing organic growth, margin improvement, and capital deployment. Investors should weigh the following considerations:
- Physician Recruiting Momentum: The record recruitment class, heavily weighted toward orthopedics, is expected to more than double its contribution in 2025, compounding organic growth.
- Integration Complexity and Costs: Elevated transaction and integration expenses in 2024 reflect higher acquisition volume and complexity, expected to normalize in 2025.
- Revenue Cycle and Procurement Upside: Early-stage initiatives in standardizing processes and leveraging scale suggest sustained margin expansion potential beyond current levels.
- Strategic Portfolio Management: Divestitures of underperforming or non-core assets optimize portfolio quality and redeploy capital to higher-growth markets.
- Regulatory Uncertainties: While site neutrality and Medicaid exposure risks appear limited, legislative developments warrant ongoing monitoring.
Risks
Potential risks include variability in acquisition timing and integration outcomes, regulatory changes impacting reimbursement, and operational execution challenges in scaling de novo facilities. The ongoing special committee review related to Bain Capital’s acquisition proposal introduces some uncertainty regarding strategic direction and associated costs. Additionally, macroeconomic factors such as labor market dynamics and inflation could affect cost structures and margin trajectories.
Forward Outlook
For Q1 2025, Surgery Partners anticipates approximately 23% of midpoint revenue guidance and 18.5% of adjusted EBITDA guidance, reflecting typical seasonality and conservative assumptions around weather-related disruptions. For full-year 2025, management projects:
- Revenue between $3.30 billion and $3.45 billion, representing 6% to 11% growth.
- Adjusted EBITDA between $555 million and $565 million, implying double-digit growth and margin expansion.
Capital deployment is expected to normalize to approximately $200 million, supporting accretive acquisitions and de novo development. Operating cash flow is forecasted to increase, though variability is expected due to acquisition timing, restructuring activities, and strategic process costs.
Takeaways
Surgery Partners’ Q4 2024 results reinforce the strength of its multi-pronged growth algorithm, combining organic expansion, margin improvement, and disciplined capital deployment. The company’s focus on high-acuity specialties and physician partnerships drives sustainable volume growth, while operational initiatives promise ongoing margin enhancement. Regulatory positioning and strong liquidity provide a stable foundation for executing the 2025 plan and beyond.
- Growth Algorithm Validation: Consistent same-facility revenue and case growth, coupled with accretive acquisitions, underpin robust financial performance.
- Operational Maturation: Early progress in revenue cycle and procurement standardization signals further margin upside as scale advantages deepen.
- Strategic Stability: Minimal Medicaid exposure and supportive site neutrality frameworks mitigate regulatory risk, reinforcing the company’s competitive positioning.
Conclusion
Surgery Partners delivered a strong finish to 2024, marked by solid organic growth and successful integration of acquisitions. The company’s strategic emphasis on specialty expansion, operational efficiency, and prudent capital management positions it well for sustained growth and margin expansion in 2025 amid a favorable regulatory backdrop.
Industry Read-Through
Surgery Partners’ results highlight the growing shift toward outpatient surgical care, particularly in high-acuity specialties like orthopedics. The company’s experience underscores the importance of physician partnerships, technological investment, and operational scale in capturing this trend. Its favorable stance on site neutrality legislation reflects broader industry dynamics favoring cost-efficient care delivery models. Other healthcare providers and investors should monitor regulatory developments and operational execution as key determinants of competitive advantage in the evolving surgical services landscape.